by hepatocytes involves a series of steps, whereby it is taken up from the blood by the hepatocytes, converted into polar glucuronic acid conjugates (bilirubin mono-and diglucuronide), and excreted across the bile canaliculus into the bile. Several inherited disorders cause plasma accumulation of unconjugated bilirubin or a combination of both unconjugated and conjugated bilirubin by affecting various steps on bilirubin throughput. 1 Of these various disorders, inherited deficiency of enzyme-catalyzed glucuronidation, which leads to CN-1, is potentially lethal. Because liver transplantation is the only definitive therapy available at this time, CN-1 is a major target for hepatocyte transplantation and gene therapy research.
Conjugation with glucuronic acid, mediated by hepatic bilirubinuridine diphosphoglucuronate glucuronosyltransferase (UGT1A1) activity, is a critical step in efficient hepatic elimination of bilirubin. 2 Therefore, the lack of function of this enzyme in CN-1 causes accumulation of unconjugated bilirubin in the plasma to 20 to 40 mg/dl, or even higher levels. 3 CN-1 carries a lifelong risk of kernicterus, and is uniformly lethal unless treated vigorously. CN-1 is caused by genetic lesions of the UGT1A1 gene, including deletions, insertions, and point mutations within the coding region of the gene or at splice donor or acceptor sites within the introns. 4 The Gunn rat, an animal model for CN-1, manifests unconjugated hyperbilirubinemia, owing to the deletion of a single guanosine residue of ugt1a1, the rat ortholog of human UGT1A1. 5 Gene therapy for CN-1 is being developed using this model.
As CN-1 does not cause an architectural abnormality of the liver, like many other inherited metabolic conditions, it could be ameliorated by partial replacement of the lacking enzyme. Replacement of 10% or more of the hepatic UGT1A1 activity by gene therapy should be therapeutically useful in preventing kernicterus in patients with CN-1. Of the various strategies employed to provide the liver of experimental animals with therapeutically significant amounts of UGT1A1 activity, most currently used methods involve vector-mediated delivery of the entire coding region of UGT1A1, driven by viral or mammalian promoters. In addition, the novel and exciting strategy of in vivo gene repair has also yielded encouraging results in Gunn rats. A brief account of gene therapy approaches is currently being evaluated, and potential strategies awaiting evaluation follow.
EX VIVO DELIVERY OF UGT1A1 TO THE LIVER
This approach involves isolation of hepatocytes from the mutant, transducing the cells in culture, using a method that leads to
Crigler -Najjar syndrome type 1 ( CN -1 ) is a potentially lethal condition, and is the only inherited disorder of bilirubin metabolism that needs treatment beyond the neonatal period. Currently, orthotopic liver transplantation is the only available cure for CN -1. Because the liver architecture is not disturbed in CN -1 and partial correction of bilirubin -UDP -glucuronosyltransferase ( UGT1A1 ) activity is expected to be sufficient for protection against kernicterus, cell and gene therapies are being developed using the Gunn rat as an animal model of the disease. Ex vivo gene therapy based on the transplantation of genetically manipulated hepatocytes and in vivo gene transfer using recombinant adenovirus and Simian virus 40 ( SV40 ) -based vectors have yielded significant success. The novel strategy of in vivo site -directed mutagenesis has also resulted in modest, but significant, correction of the genetic abnormality. Newer viral and nonviral gene delivery methods are being explored and have been discussed in brief. In summary, effective gene therapy methods have been validated in Gunn rats. Despite considerable remaining hurdles, gene therapy for CN -1 could become a clinical reality by the turn of this decade. Journal of Perinatology 2001; 21:S114 -S118.
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integration of the therapeutic gene to the donor cell genome and then transplanting the phenotypically corrected cell back into the donor. As the hepatocytes are autologous, immunosuppression is not necessary. 6 To improve the efficiency of integration of the therapeutic gene (human UGT1A1), proliferation of the isolated hepatocytes in culture has been stimulated by transferring the gene for a mutant SV40 T antigen that is expressed at permissive temperatures (338C), but is degraded at physiological temperatures (378C to 398C). 7 
DELIVERY OF UGT1A1 TO THE LIVER IN VIVO
The coding region of UGT1A1 can be delivered to the Gunn rat liver, providing bilirubin glucuronidating activity. Although several nonviral methods to deliver the transgene to the liver have been evaluated, to date, viral vectors remain the mainstay of liver-directed gene therapy.
Nonviral Vectors for Gene Transfer
Receptor-mediated endocytosis. The asialoglycoprotein receptor (ASGPr) is expressed selectively in the liver. Macromolecules, such as DNA, can be linked to ligands, such as galactose-containing peptides or galactosylated polycations, so that upon systemic administration, the DNA is taken up specifically by hepatocytes. ASGPr-mediated endocytosis has been used in more than one method of gene therapy for CN-1. Efficiency of this method is limited by the fact that DNA introduced into hepatocytes by this method tends to be routed to lysosomes and be destroyed within 48 hours. This problem can be partly circumvented by depolymerization of microtubules or disruption of the endosomes after endocytosis. 8, 9 Asialoorsomucoid, a ligand to ASGPr, was conjugated with polylysine and electrostatically bound to a plasmid expressing UGT1A1. The plasmid DNA-carrier complex is taken up selectively by the liver. Partial hepatectomy or treatment with colchicine around the time of gene introduction disrupts the microtubules, thereby prolonging the persistence of the transgene. 8, 9 F virosome-mediated gene transfer. The F protein of the envelope of the hemagglutinating virus of Japan (HVJ) has fusogenic properties and is naturally galactose-terminated. After intravenous injection in Gunn rats of a plasmid expressing human UGT1A1, packaged in the ''F virosomes,'' serum bilirubin levels declined by 40% and bilirubin glucuronides were detectable in the bile. The levels remained reduced for the duration of the study (50 days). 10 The F virosomal vector is nonimmunogenic. This nonviral gene delivery method promises to be a useful tool.
Receptor-mediated delivery has also been employed for repairing the genetic lesion of ugt1a1 in Gunn rats in vivo (vide infra).
Viral Vectors in Gene Therapy of CN-1
Viruses have evolved mechanisms to enter the nucleus of the host cell, express genes, and replicate. Some viruses integrate their genetic material into the host genome. These characteristics can be exploited for transgene delivery by packaging the DNA into a viral genome. Recombinant viruses are made replication-defective by deleting most of their genes or a critical transactivating gene. Each of the several viral agents that are currently being tried in liver-directed gene therapy has some advantages and limitations. The following sections discuss the different viral vectors that have been tested in the Gunn rat.
Retroviral Vectors
Retroviruses contain RNA genomes that are transcribed into complementary DNA after entering the cell. The complementary DNA is integrated into the host genome. Recombinant retroviruses accept large transgenes and can be grown at relatively high titers. They do not elicit significant host immune response. Recombinant retroviruses can be constructed so that they cannot activate a dormant oncogene or initiate transcription of the viral proteins from the integrated provirus. This is achieved by introducing deletions in the long terminal repeats (LTRs) of the genome that carry viral promoters and enhancers. The transgene is usually expressed from a separate internal promoter. Retroviruses expressing UGT1A1, based on the Moloney's murine leukemia virus (MoMuLV), have been used to treat Gunn rats. Long-term reduction in serum bilirubin levels has been achieved by exsanguinous perfusion of the liver with this preparation. 11 However, MoMuLV requires cell division for integration and is inefficient in gene transfer into quiescent hepatocytes. The host needs to be manipulated to induce hepatocellular mitosis to achieve high transduction efficiency. Lentiviruses are another group of retroviruses that can integrate into the host genome even in cells that are not in mitosis. Pseudotyped lentiviral vectors, based on HIV-IV, have been developed for gene therapy of CN-1. However, hepatocytes may need to have entered the cell cycle for lentiviral vectors to integrate.
Adenoviral Vectors
Recombinant adenoviruses are the most efficient gene delivery vehicles to the liver. Upon systemic administration, they localize specifically in the liver 8 and transduce both dividing and nondividing cells. In sufficient doses, these agents can transduce nearly all hepatocytes in the intact liver. Adenoviral vectors have been extensively used in transferring UGT1A1 into the Gunn rat livers.
Recombinant adenoviruses are derived from human adenovirus types 5 and 2. The E1 region that codes for the transacting proteins for the viral genes is disrupted by inserting the transgene. The recombinant viruses are generated in cell lines that provide E1 encoded proteins in trans. These viruses can be grown at high titers and purified. Notwithstanding the above characteristics that would have made adenoviruses attractive for liver-directed gene therapy, there are some major shortcomings of these agents. Adenoviruses remain episomal in the host cell and the benefits of gene expression are short-lived. In addition, the high immunogenecity of adenoviruses evokes severe host immune responses that lead to the elimination of the vector and cytotoxic lymphocyte-mediated liver damage, precluding repeated administration.
Strategies of modification of the host or the vector have been explored to reduce the immunogenicity of adenoviruses. Administration of recombinant adenoviral vectors to newborn Gunn rats induces lifelong tolerance to the viral antigens and permits repeated administration. 12 Tolerance can be induced also by injecting adenoviral proteins into the thymus of young, adult rats. 13 Tolerization of the host to adenoviruses by oral feeding of adenoviral proteins in low doses not only permits repeat administration in naive hosts, but also allows administration in preimmunized hosts.
14 Alternatively, coadministration of the immunosuppressive agent FK-506 for 3 days around the time of administration of adenoviruses prevents both cellular and humoral immune responses. 15 However, this procedure produces immune ignorance, rather than tolerance, and therefore, FK-506 must be administered every time adenoviral vectors are introduced.
Modification of the vector has also been used to subdue its immunogenecity. Despite deletion of all structural genes of adenoviruses, the ''gutless'' vectors retain their immunogenicity. Adenoviral E3 gene-encoded proteins provide a natural mechanism that these viruses have evolved to prolong their survival by host immunomodulation. Recombinant viruses that express the immunomodulatory E3 proteins via a separate promoter have been used with some success. 16 Another imaginative strategy involves construction of adenoviral vectors that express both UGT1A1 and the immunomodulatory protein CTLA4Ig under independent promoters. CTLA4Ig inhibits the costimulatory mechanisms between the antigen-presenting cells and the cytotoxic T lymphocytes. Initial results with such modified vectors have permitted high levels of gene expression for more than a year from a single administration in UGT1A1-deficient Gunn rats. 17 The safety concerns involved in host tolerization to a potentially pathogenic virus have provided the impetus to develop other viral agents, such as those based on SV40 and adenoassociated viruses.
SV40 is a DNA virus of the papova family. Recombinant SV40 viruses are constructed by deleting the T antigen coding sequences from its genome and replacing it with the gene of interest. The viruses are packaged in COS cells that provide the T antigen in trans. They can be grown and purified at high titers. Removal of T antigen renders the agent both nonimmunogenic and replication-deficient.
SV40-based vectors have been used for gene therapy of Gunn rats with significant success. 18 The virus integrates into the host genome and the gene product is expressed permanently. Although the integration is not site-specific, no noticeable adverse effects were observed. Moreover, the follow up for more than 40 years of thousands of subjects who got inadvertently infected with SV40 viruses contaminating polio vaccines showed no untoward effects statistically associated with the infection. SV40 viruses do not localize specifically into the liver, and transgene expression occurs in many organs.
SITE-DIRECTED GENE REPAIR
In vivo gene repair is a fascinating approach that has been developed in recent years to treat single nucleotide mutations of deletions. This strategy exploits the natural cellular gene repair mechanisms. The repair process is initiated by transfecting a double-stranded RNA-DNA chimeric molecule. The sequence of the central region of the RNA/DNA chimera is complementary to the site in the genome that is targeted for repair, except for a single basepair mismatch in the DNA sequence, corresponding to the nucleotide that is intended to be repaired. The DNA sequences are flanked by modified RNA sequences, which are in turn flanked by core DNA sequences. The molecule is designed in a manner that permits formation of hairpin loops at both ends and formation of a double-stranded structure with a single nick. The RNA component of the molecule is thought to provide improved basepairing ability. Upon entry into the nucleus, the chimeric molecule anneals to its target site, creating a single base mismatch. This stimulates the cellular mismatch repair system, thereby correcting the single base mismatch in the genome.
This technique has been used to introduce missense mutations in the alkaline phosphatase gene of human hepatoma cell lines and in the factor IX gene in mouse endothelial cells in vivo. Recently, the deleted guanosine residue in the Gunn rat ugt1a1 5 was inserted by administering a chimeric oligonucleotide designed on the basis of the above principles. 19 The corrected cells synthesized catalytically active ugt1a1 resulting in a fall in bilirubin levels by 40%. The bile showed excretion of bilirubin glucuronides. The effect of gene correction is permanent and as the gene expression is controlled by the natural promoter and enhancer elements, physiological modulation of expression is retained. In Gunn rats, the chimeric molecule was administered complexed to a galactose-terminated polyethyleneimine. The therapeutic molecule was delivered to the liver by receptormediated endocytosis. As usual for receptor-mediated endocytosis, the internalized macromolecules persist for a limited period only (24 hours), during which the mismatch repair must occur. Conceivably, improved gene conversion could be achieved in the future with improved methods of delivery of the chimera to the nucleus.
POTENTIAL NOVEL METHODS FOR GENE THERAPY OF CN-1
Research on gene therapy for CN-1 has kept pace with the development of new vectors. In addition, efforts are being made to improve upon the existing ones. Notably, the genome of recombinant adenoviruses is being altered to reduce their immunogenecity. Two new strategies that are promising for gene therapy of CN-1 are discussed briefly below.
Recombinant AAV Adenoassociated virus type 2 (AAV-2) is a small DNA virus of the parvovirus family. For purposes of gene therapy, the most attractive feature of this virus is that it integrates sitespecifically in the host genome on the q13.4-ter arm of human chromosome 19. Such a specific integration could reduce the risk of activation of a dormant oncogene. In fact, AAV-2 integrated in the human chromosome remains latent without causing any untoward effect. However, in usual recombinant AAV vectors, the site specificity of integration is lost. Similar to the SV40 vectors, AAV-2 does not localize specifically to the liver on systemic administration. These vectors evoke a humoral immune response in the host, which may limit its readministration.
Gene Transposition
Transposons are natural genetic elements that are capable of moving genes from one part of the genome to another. Transposons belonging to the Tc1/mariner superfamily have been studied most extensively. These transposons transpose genetic material by a ''cut-and-paste'' mechanism. Transposons are flanked by inverted repeats (IRs). The transposase, which is expressed from the transposon, excises the transposon at specific sites in the IRs and pastes it at a different location in the genome. Upon cotransfection of host cells with two plasmids, one containing a transposon IR-flanked target transgene and the other encoding the transposase, target gene is integrated into the host genome. Initial results with this system in hemophilic mice have been encouraging, although the transduction rate is low. 20 The safety of random integration of foreign genetic material by transposition needs to be evaluated.
In summary, both ex vivo (mediated by isolated hepatocytes) and in vivo gene approaches are being pursued in preclinical research for developing safe and effective treatment of CN-1. Gene transfer vectors, based on recombinant viruses, such as murine leukemia virus, adenovirus, and SV40, have been employed successfully in transferring the therapeutic gene (UGT1A1) to the liver of UGT1A1-deficient jaundiced Gunn rats. Alternative strategies utilize nonviral vectors, such as liposomes, or galactosylated carrier substances that can mediated receptormediated DNA delivery, specifically to hepatocytes. A transposontransposase system is being utilized to augment integration of the transferred gene into the genome of hepatocytes. A novel strategy based on in vivo site-directed mutagenesis has also resulted in significant amelioration of the metabolic abnormality. Despite lingering safety and efficiency issues, gene therapy promises to be a realistic modality in the treatment of CN-1 during the coming decade.
